Adial Pharmaceuticals enters ATM equity offering of up to $4.28M with H.C. Wainwright

ADIAL PHARMACEUTICALS, INC.

At-the-market offering of common stock up to $4,283,650 based on Form S-3 limitations.
Sales agent H.C. Wainwright receives 3% commission on gross proceeds from each sale.
Company to reimburse Wainwright up to $50,000 in expenses, plus $2,500 per due diligence update.
Offering continues until all shares sold or the agreement is terminated.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ADIAL PHARMACEUTICALS, INC. entered into At the Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2024-04-18).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2024-04-18

Exact text from the filing

On April 18, 2024, Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”) providing for the sale by the Company of its shares of common stock, par value $0.001 per share (the “Common Stock”), from time to time, through the Sales Agent, with certain limitations on the amount of Common Stock that may be offered and sold by the Company as set forth in the ATM Agreement (the “Offering”).

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-034186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.